8,9-dehydroasterolide, atractylenolide I
Name | Atractylenolide I | ||
PubChem CID | 5321018 | ||
Molecular Weight | 230.30g/mol | ||
Synonyms |
8,9-dehydroasterolide, atractylenolide I |
||
Formula | C₁₅H₁₈O₂ | ||
SMILES | CC1=C2CC3C(=C)CCCC3(C=C2OC1=O)C | ||
InChI | 1S/C15H18O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h8,12H,1,4-7H2,2-3H3/t12-,15+/m0/s1 | ||
InChIKey | ZTVSGQPHMUYCRS-SWLSCSKDSA-N | ||
CAS Number | 73069-13-3 | ||
ChEMBL ID | CHEMBL449520 | ||
KEGG ID | C17885 | ||
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | FuLing | ||
Use Part | Sclerotium | ||
Habitat | YunNan, HeBei, ShanDong, SiChuan | ||
Flavor | Sweet, Bland | ||
Meridian Tropism | Heart, Lung, Spleen, Kidney |
Chineses Pinyin | FuLingPi | ||
Use Part | Sclerotium Dried Skin | ||
Habitat | AnHui, YunNan, HuBei | ||
Flavor | Sweet, Bland | ||
Meridian Tropism | Lung, Spleen, Kidney |
Chineses Pinyin | BaiZhu | ||
Use Part | Root | ||
Habitat | AnHui, ZheJiang, JiangXi | ||
Flavor | Bitter, Sweet | ||
Meridian Tropism | Spleen, Stomach | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Asterales
-->Family: Asteraceae
-->Genus: Atractylodes
-->Species: Atractylodes macrocephala
|
Chineses Pinyin | CangZhu | ||
Use Part | Rhizome | ||
Habitat | HeNan, ShanDong | ||
Flavor | Pungent, Bitter | ||
Meridian Tropism | Spleen, Stomach, Liver | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Asterales
-->Family: Asteraceae
-->Genus: Atractylodes
-->Species: Atractylodes lancea
|
Pair Name | Atractylenolide I, Erlotinib | |||
Partner Name | Erlotinib | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Gene Regulation | Down-regulation | Expression | CYB5R2 | hsa51700 |
Down-regulation | Expression | EZH2 | hsa2146 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
In Vivo Model | A549 cells, carrying the luciferase reporter gene (1×10⁷ cells), were subcutaneously injectinto the mice. | |||
Result | Targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer |
Pair Name | Atractylenolide I, Cabozantinib | |||
Partner Name | Cabozantinib | |||
Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Expression | CASP3 | hsa836 | |
Up-regulation | Expression | CDH1 | hsa999 | |
Up-regulation | Expression | PARP1 | hsa142 | |
Down-regulation | Expression | VIM | hsa7431 | |
In Vitro Model | DU145 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0105 |
PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 | |
Result | Silencing Hsp27 inhibits EMT. ATL-1 can inhibit the malignant evolution of prostate cancer cells by inhibiting Hsp27/eIF4E. ATL-1 also enhanced chemosensitization of cabozantinib in prostate cancer. |
No. | Title | Href |
---|---|---|
1 | Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells. Cell Physiol Biochem. 2018;49(4):1615-1632. doi: 10.1159/000493497. | Click |
2 | Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27. Front Oncol. 2023 Jan 6;12:1084884. doi: 10.3389/fonc.2022.1084884. | Click |